Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) have been assigned a consensus recommendation of “Hold” from the nine research firms that are currently covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $4.14.

Several research firms have recently issued reports on FATE. Wall Street Zen raised shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 15th. Stifel Nicolaus lowered their price objective on shares of Fate Therapeutics from $5.00 to $3.00 and set a “hold” rating for the company in a research note on Thursday, March 6th. Needham & Company LLC reissued a “hold” rating on shares of Fate Therapeutics in a research report on Wednesday, May 14th. Barclays decreased their price target on Fate Therapeutics from $10.00 to $2.00 and set an “overweight” rating for the company in a report on Wednesday, May 14th. Finally, Wells Fargo & Company reduced their target price on Fate Therapeutics from $5.00 to $4.00 and set an “equal weight” rating for the company in a report on Thursday, March 6th.

Fate Therapeutics Price Performance

Shares of NASDAQ:FATE opened at $1.16 on Tuesday. The company has a market cap of $132.94 million, a price-to-earnings ratio of -0.70 and a beta of 2.32. The firm has a 50 day simple moving average of $1.04 and a 200 day simple moving average of $1.44. Fate Therapeutics has a one year low of $0.66 and a one year high of $5.92.

Fate Therapeutics (NASDAQ:FATE) last posted its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.07. The firm had revenue of $1.63 million during the quarter, compared to the consensus estimate of $1.18 million. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. As a group, analysts expect that Fate Therapeutics will post -1.63 EPS for the current year.

Hedge Funds Weigh In On Fate Therapeutics

A number of large investors have recently made changes to their positions in the stock. Graham Capital Management L.P. bought a new position in shares of Fate Therapeutics in the fourth quarter valued at approximately $37,000. China Universal Asset Management Co. Ltd. bought a new position in Fate Therapeutics in the 4th quarter valued at $40,000. Brevan Howard Capital Management LP bought a new stake in Fate Therapeutics during the fourth quarter valued at $41,000. FPC Investment Advisory Inc. bought a new stake in Fate Therapeutics during the fourth quarter valued at $44,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Fate Therapeutics during the fourth quarter valued at $55,000. 97.54% of the stock is owned by institutional investors.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.